What to check before you switch
Before moving any volume, confirm the platform layer change does not disrupt the pharmacy layer underneath — or leave a gap in 503B coverage. First, check formulary fit: list your highest-volume SKUs — semaglutide, tirzepatide, your hormone and peptide lines — and confirm the LegitScript-certified 503A partners assigned to your Fizy Health clinic can fill them. Because both BoomRx and Fizy Health are ordering platforms, not compounders, the actual medications come from pharmacy partners. If your clinic relies on FDA-registered 503B office-use products or brand medications available only through BoomRx's hub, plan to keep those lines on BoomRx while you migrate patient-specific 503A refills.
Second, review your existing BoomRx agreement for any notice period, minimum commitment, or termination terms before you reduce volume — these are clinic-specific contract details you should read in your own agreement rather than assume. Third, decide what data you carry over: patient demographics, your common SIGs, and your repeat-order SKUs. None of this requires an EMR migration — procurement platforms live alongside your chart system, not in place of it. BoomRx's EMR and API integrations route orders from your clinical stack; switching patient-linked checkout on Fizy Health does not require unplugging those integrations for the SKUs you keep on BoomRx.